Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model
Open Access
- 26 August 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e71505
Abstract
Warfarin is the most frequently prescribed anticoagulant worldwide. However, warfarin therapy is associated with a high risk of bleeding and thromboembolic events because of a large interindividual dose-response variability. We investigated the effect of genetic and non genetic factors on warfarin dosage in a South Italian population in the attempt to setup an algorithm easily applicable in the clinical practice. A total of 266 patients from Southern Italy affected by cardiovascular diseases were enrolled and their clinical and anamnestic data recorded. All patients were genotyped for CYP2C9*2,*3, CYP4F2*3, VKORC1 -1639 G>A by the TaqMan assay and for variants VKORC1 1173 C>T and VKORC1 3730 G>A by denaturing high performance liquid chromatography and direct sequencing. The effect of genetic and not genetic factors on warfarin dose variability was tested by multiple linear regression analysis, and an algorithm based on our data was established and then validated by the Jackknife procedure. Warfarin dose variability was influenced, in decreasing order, by VKORC1-1639 G>A (29.7%), CYP2C9*3 (11.8%), age (8.5%), CYP2C9*2 (3.5%), gender (2.0%) and lastly CYP4F2*3 (1.7%); VKORC1 1173 C>T and VKORC1 3730 G>A exerted a slight effect (2 = 0.805 and p2 = 0.773, respectively). Our algorithm, which is based on six polymorphisms, age and gender, is user-friendly and its application in clinical practice could improve the personalized management of patients undergoing warfarin therapy.Keywords
This publication has 47 references indexed in Scilit:
- Influence of CYP4F2 genotype on warfarin dose requirement–a systematic review and meta-analysisThrombosis Research, 2012
- Genetic Warfarin DosingJACC, 2011
- VKORC1 , CYP2C9 and CYP4F2 Genetic-based Algorithm for Warfarin Dosing: An Italian Retrospective StudyPharmacogenomics, 2010
- Warfarin Versus New Agents: Interpreting the DataHematology-American Society Hematology Education Program, 2010
- Combined CYP2C9 , VKORC1 and CYP4F2 Frequencies among Racial and Ethnic GroupsPharmacogenomics, 2010
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin DosingClinical Pharmacology & Therapeutics, 2010
- A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic OpportunityThe Journal of Clinical Pharmacology, 2009
- Dynamic Pharmacogenetic Models in Anticoagulation TherapyClinics In Laboratory Medicine, 2008
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- 3'-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperaturesNucleic Acids Research, 2000